Published in Clin Cancer Res on April 15, 2006
Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol (2011) 1.98
Chemokines in tumor progression and metastasis. Oncotarget (2013) 1.64
Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol (2008) 1.48
CXCR4/CXCL12 axis in non small cell lung cancer (NSCLC) pathologic roles and therapeutic potential. Theranostics (2013) 1.35
CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol (2010) 1.15
The role of immunoglobulin superfamily cell adhesion molecules in cancer metastasis. Int J Cell Biol (2012) 1.15
Chemokine signaling in cancer: one hump or two? Semin Cancer Biol (2008) 1.04
Melanocyte receptors: clinical implications and therapeutic relevance. Dermatol Clin (2007) 1.01
IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment. Neoplasia (2012) 0.99
CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma. World J Gastroenterol (2011) 0.98
G-protein-coupled receptors and melanoma. Pigment Cell Melanoma Res (2008) 0.97
NF-κB inducing kinase (NIK) modulates melanoma tumorigenesis by regulating expression of pro-survival factors through the β-catenin pathway. Oncogene (2011) 0.97
Expression and functional role of CRIPTO-1 in cutaneous melanoma. Br J Cancer (2011) 0.96
The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis (2007) 0.95
Melanoma biomolecules: independently identified but functionally intertwined. Front Oncol (2013) 0.95
Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest (2013) 0.92
Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases. PLoS One (2013) 0.92
Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation. Oncogene (2008) 0.92
Chemokine receptor-specific antibodies in cancer immunotherapy: achievements and challenges. Front Immunol (2015) 0.91
Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis (2007) 0.90
Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin Cancer Biol (2008) 0.90
Clinical utilization of chemokines to combat cancer: the double-edged sword. Expert Rev Vaccines (2007) 0.89
Chemokine receptor CXCR4 is a novel marker for the progression of cutaneous malignant melanomas. Acta Histochem Cytochem (2012) 0.86
CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma. Clin Exp Metastasis (2012) 0.81
Tie-2 regulates the stemness and metastatic properties of prostate cancer cells. Oncotarget (2016) 0.80
PAX3 and FOXD3 Promote CXCR4 Expression in Melanoma. J Biol Chem (2015) 0.78
Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. Biomed Res Int (2014) 0.77
Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis. Curr Top Med Chem (2014) 0.77
CXCR4 pathway associated with family history of melanoma. Cancer Causes Control (2013) 0.76
In vitro characterization and inhibition of the CXCR4/CXCL12 chemokine axis in human uveal melanoma cell lines. Cancer Cell Int (2007) 0.76
CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget (2016) 0.76
Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. Int J Endocrinol (2014) 0.75
The Hydrogen Sulfide Releasing Molecule Acetyl Deacylasadisulfide Inhibits Metastatic Melanoma. Front Pharmacol (2017) 0.75
A clinicopathological analysis of primary mucosal malignant melanoma. Surg Today (2014) 0.75
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology (2012) 5.75
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 5.43
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21
Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88
The immune score as a new possible approach for the classification of cancer. J Transl Med (2012) 2.79
The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg (2009) 2.44
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol (2012) 2.41
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
GPR30 is overexpressed in post-puberal testicular germ cell tumors. Cancer Biol Ther (2011) 2.20
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol (2012) 2.03
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
The role of BRAF V600 mutation in melanoma. J Transl Med (2012) 2.00
Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol (2005) 1.88
p53 suppresses the Nrf2-dependent transcription of antioxidant response genes. J Biol Chem (2006) 1.84
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol (2004) 1.83
Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology (2010) 1.76
Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle (2010) 1.73
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol (2009) 1.71
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics (2010) 1.68
Main roads to melanoma. J Transl Med (2009) 1.67
Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer (2010) 1.66
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle (2007) 1.65
The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat (2011) 1.65
Locoregional spread of cutaneous melanoma: sonography findings. AJR Am J Roentgenol (2010) 1.60
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med (2012) 1.60
NeuroD1 expression in human prostate cancer: can it contribute to neuroendocrine differentiation comprehension? Eur Urol (2006) 1.59
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59
EGFR mutational status in penile cancer. Expert Opin Ther Targets (2013) 1.57
Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab (2003) 1.50
Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One (2011) 1.48
Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 1.48
Clinical genetic testing for familial melanoma in Italy: a cooperative study. J Am Acad Dermatol (2009) 1.45
Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol (2010) 1.45
Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest (2006) 1.44
Laminin-5 mutational analysis in an Italian cohort of patients with junctional epidermolysis bullosa. J Invest Dermatol (2004) 1.42
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9). Oncology (2014) 1.41
Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab (2002) 1.40
Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res (2006) 1.37
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol (2006) 1.37
Kindler syndrome: extension of FERMT1 mutational spectrum and natural history. Hum Mutat (2011) 1.36
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Cell-surface sensors for real-time probing of cellular environments. Nat Nanotechnol (2011) 1.28
BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol (2011) 1.27
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics (2013) 1.24
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunol Immunother (2014) 1.23
HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res (2004) 1.23
Renal cell carcinoma with solitary toe metastasis. Int J Urol (2005) 1.22
Polyomavirus BK-specific immunity after kidney transplantation. Transplantation (2004) 1.22
Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis (2005) 1.18
Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas. Am J Pathol (2010) 1.18
Identification of cripto-1 as a novel serologic marker for breast and colon cancer. Clin Cancer Res (2006) 1.18
Myopathic lamin mutations impair nuclear stability in cells and tissue and disrupt nucleo-cytoskeletal coupling. Hum Mol Genet (2013) 1.17
Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer (2012) 1.17
Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis (2008) 1.17
EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol (2012) 1.16
HMGA2 mRNA expression correlates with the malignant phenotype in human thyroid neoplasias. Eur J Cancer (2008) 1.14
Metastatic eccrine porocarcinoma: report of a case and review of the literature. World J Surg Oncol (2011) 1.13
Analysis of human papillomavirus type-16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer. J Med Virol (2004) 1.13
TAZ/WWTR1 is overexpressed in papillary thyroid carcinoma. Eur J Cancer (2010) 1.12
Fe65, a ligand of the Alzheimer's beta-amyloid precursor protein, blocks cell cycle progression by down-regulating thymidylate synthase expression. J Biol Chem (2002) 1.12
The ubiquitin-proteasome system contributes to the inflammatory injury in ischemic diabetic myocardium: the role of glycemic control. Cardiovasc Pathol (2009) 1.11
Sclerosing polycystic adenosis of the parotid gland: report of one case diagnosed by fine-needle cytology with in situ malignant transformation. Diagn Cytopathol (2010) 1.11